- Home
- LX vs PRTC Comparison
LX vs PRTC Comparison
Compare LX & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LX | PRTC |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.4M | 464.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | LX | PRTC |
|---|---|---|
| Price | $2.71 | $16.81 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 3.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 14.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $2.08 | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $13.30 |
| 52 Week High | $11.64 | $20.00 |
Technical Indicators
Market Signals| Indicator | LX | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 48.59 |
| Support Level | $2.62 | $16.51 |
| Resistance Level | $3.10 | $18.10 |
| Average True Range (ATR) | 0.12 | 0.49 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 23.86 | 44.66 |
Price Performance
Historical ComparisonAbout LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.